Expanding access to long-acting HIV therapy in low-income and middle-income countries
▶

Expanding access to long-acting HIV therapy in low-income and middle-income countries

Taking HIV treatment daily is not just a routine, it may be a struggle. For many like Nancy, the emotional and physical toll of taking pills every day can be overwhelming. Long-acting injectable HIV treatment offers hope. It’s safe, effective, and highly preferred in some settings. But low- and middle-income countries still need timely access. Voluntary licensing can bridge that gap, ensuring that the most vulnerable aren't the last to benefit from innovation. 🔗 Read more in The Lancet Global Health: https://www.sciencedirect.com/science/article/pii/S2214109X25002803